UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Public investments in the development of GeneXpert molecular diagnostic technology

PloS one, 2021-08, Vol.16 (8), p.e0256883-e0256883

2021

Volltextzugriff (PDF)

Public investments in the clinical development of bedaquiline

PloS one, 2020-09, Vol.15 (9), p.e0239118-e0239118

2020

Volltextzugriff (PDF)

Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis

PloS one, 2024-10, Vol.19 (10), p.e0309034

2024

Volltextzugriff (PDF)

Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

PloS one, 2024-01, Vol.19 (1), p.e0296448-e0296448

2024

Volltextzugriff (PDF)

Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study

PloS one, 2024-08, Vol.19 (8), p.e0308118

2024

Volltextzugriff (PDF)

Cell line access to revolutionize the biosimilars market

F1000 research, 2018, Vol.7, p.537-537

Gotham, Dzintars

2018

Volltextzugriff (PDF)

Improving the availability of antihypertensive drugs in the India Hypertension Control Initiative, India, 2019-2020

PloS one, 2023-12, Vol.18 (12), p.e0295338-e0295338

2023

Volltextzugriff (PDF)

Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation

PloS one, 2024-05, Vol.19 (5), p.e0301716-e0301716

2024

Volltextzugriff (PDF)

German funders' data sharing policies-A qualitative interview study

PloS one, 2024-02, Vol.19 (2), p.e0296956

2024

Volltextzugriff (PDF)

A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model

PloS one, 2023-12, Vol.18 (12), p.e0294560-e0294560

2023

Volltextzugriff (PDF)

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab

PloS one, 2024-02, Vol.19 (2), p.e0293264-e0293264

2024

Volltextzugriff (PDF)

Management of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq

PloS one, 2024-01, Vol.19 (1), p.e0296952-e0296952

2024

Volltextzugriff (PDF)

Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment

PloS one, 2023-10, Vol.18 (10), p.e0292106-e0292106

2023

Volltextzugriff (PDF)

Standard diagnostics with and without urine-based lipoarabinomannan testing for tuberculosis disease in HIV-infected patients in a high-burden setting-A cost-effectiveness analysis

PloS one, 2023-07, Vol.18 (7), p.e0288605-e0288605

2023

Volltextzugriff (PDF)

Trends in cost and consumption of essential medicines for non-communicable diseases in Azerbaijan, Georgia, and Uzbekistan, from 2019 to 2021

PloS one, 2023-12, Vol.18 (12), p.e0294680-e0294680

2023

Volltextzugriff (PDF)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Journal of Virus Eradication, 2018-04, Vol.4 (2), p.72-79

2018

Volltextzugriff (PDF)

Correction: Global health research and education at medical faculties in Germany

PloS one, 2022-01, Vol.17 (1), p.e0263556-e0263556

2022

Volltextzugriff (PDF)

Global health research and education at medical faculties in Germany

PloS one, 2020-04, Vol.15 (4), p.e0231302-e0231302

2020

Volltextzugriff (PDF)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Journal of Virus Eradication, 2020-09, Vol.6 (3), p.100001-100001, Article 100001

2020

Volltextzugriff (PDF)

Quantifying changes in global health inequality: the Gini and Slope Inequality Indices applied to the Global Burden of Disease data, 1990–2017

BMJ global health, 2019-09, Vol.4 (5), p.e001500-e001500

2019

Volltextzugriff (PDF)

How the MDGs gave up on measuring access to medicines

The Lancet global health, 2016-05, Vol.4 (5), p.e296-e297

2016

Volltextzugriff (PDF)

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

Journal of Virus Eradication, 2015-04, Vol.1 (2), p.103-110

2015

Volltextzugriff (PDF)

Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States

Health policy (Amsterdam), 2021-03, Vol.125 (3), p.296-306

2021

Volltextzugriff (PDF)

Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials

AIDS (London), 2020-12, Vol.34 (15), p.2259-2268

2020

Volltextzugriff (PDF)

Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide

Current opinion in HIV & AIDS, 2017-07, Vol.12 (4), p.324-333

2017

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(24)
Humans
(19)
Multidisciplinary Sciences
(13)
Science & Technology - Other Topics
(13)
Global Health
(11)
Medicine And Health Sciences
(11)
Social Sciences
(9)
Infectious Diseases
(8)
Tuberculosis
(8)
Drug Dosages
(7)
Drug Resistance
(7)
Drugs
(7)
Patients
(7)
Prices
(7)
Analysis
(6)
Care And Treatment
(6)
Diagnosis
(6)
General & Internal Medicine
(6)
Immunology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Plos One
(19)
Journal Of Virus Eradication
(5)
Bmj Global Health
(3)
Bmj Open
(3)
Gabi Journal
(3)
The Lancet Global Health
(3)
The lancet. Global Health/the lancet. Global Health
(2)
Aids
(1)
Bmj
(1)
Bulletin Of The World Health Organization
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Public investments in the development of GeneXpert molecular diagnostic technology

Public investments in the clinical development of bedaquiline

Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis

Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study

Cell line access to revolutionize the biosimilars market

Improving the availability of antihypertensive drugs in the India Hypertension Control Initiative, India, 2019-2020

Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation

German funders' data sharing policies-A qualitative interview study

A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab

Management of rifampicin-resistant tuberculosis in conflict-affected areas: The case of Iraq

Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment

Standard diagnostics with and without urine-based lipoarabinomannan testing for tuberculosis disease in HIV-infected patients in a high-burden setting-A cost-effectiveness analysis

Trends in cost and consumption of essential medicines for non-communicable diseases in Azerbaijan, Georgia, and Uzbekistan, from 2019 to 2021

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Correction: Global health research and education at medical faculties in Germany

Global health research and education at medical faculties in Germany

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Quantifying changes in global health inequality: the Gini and Slope Inequality Indices applied to the Global Burden of Disease data, 1990–2017

How the MDGs gave up on measuring access to medicines

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States

Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials

Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide

Suchergebnisse filtern